Zacks Research Issues Negative Estimate for Qiagen Earnings

Qiagen (NYSE:QGEN) – Stock analysts at Zacks Research cut their Q4 2025 EPS estimates for Qiagen in a report released on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the company will earn $0.63 per share for the quarter, down from their previous estimate of $0.64. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q1 2026 earnings at $0.51 EPS and FY2027 earnings at $2.69 EPS.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%.

Other equities research analysts also recently issued reports about the stock. Morgan Stanley reissued an “equal weight” rating and set a $46.67 target price (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Jefferies Financial Group reissued a “buy” rating and set a $52.50 target price (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Robert W. Baird downgraded shares of Qiagen from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $52.00 to $42.00 in a research report on Wednesday, February 19th. Baird R W downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Finally, UBS Group decreased their target price on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $47.71.

Qiagen Trading Down 0.2 %

NYSE:QGEN opened at $38.32 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The firm has a 50-day moving average of $42.61 and a 200-day moving average of $42.87. The company has a market cap of $8.50 billion, a PE ratio of 106.70, a PEG ratio of 2.39 and a beta of 0.36. Qiagen has a one year low of $38.15 and a one year high of $49.30.

Institutional Investors Weigh In On Qiagen

A number of institutional investors have recently added to or reduced their stakes in the company. State Street Corp grew its position in shares of Qiagen by 3.9% during the 3rd quarter. State Street Corp now owns 2,380,008 shares of the company’s stock valued at $108,457,000 after acquiring an additional 90,181 shares during the period. Jennison Associates LLC grew its position in shares of Qiagen by 5.0% during the 3rd quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock valued at $65,001,000 after acquiring an additional 68,415 shares during the period. XTX Topco Ltd grew its position in shares of Qiagen by 129.3% during the 3rd quarter. XTX Topco Ltd now owns 20,192 shares of the company’s stock valued at $920,000 after acquiring an additional 11,385 shares during the period. Sanctuary Advisors LLC grew its position in shares of Qiagen by 24.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock valued at $834,000 after acquiring an additional 3,878 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Qiagen by 36.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock valued at $73,096,000 after acquiring an additional 424,937 shares during the period. 70.00% of the stock is owned by institutional investors.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.